LuciDabra 75 mg Capsule

Prescription Required

Brand Name:

LuciDabra

Molecule:

Dabrafenib

Strength:

75 mg

Quantity:

120 Capsules

Form:

Capsule

Packaging Type:

Bottle

Manufacturer/Marketed By:

Lucius Pharma

Country of Origin:

Loas

Categories: Oncology, Skin Cancer

No similar products found.

Description

LuciDabra (Dabrafenib) is a revolutionary kinase inhibitor that targets patients with unresectable or metastatic melanoma harboring the BRAF V600E mutation. Designed for efficacy, LuciDabra is not only effective as a standalone treatment but also works synergistically with trametinib for enhanced outcomes. This powerful formulation is indicated for:

The treatment of unresectable or metastatic melanoma with BRAF V600E or V600K mutations.
Adjuvant therapy for patients post-complete resection of melanoma with BRAF V600E or V600K mutations and lymph node involvement.
The treatment of metastatic non-small cell lung cancer (NSCLC) with the BRAF V600E mutation.

With LuciDabra Dabrafenib 20 mg, patients receive a targeted approach that focuses on their genetic profile, maximizes treatment potential, and improves quality of life. Choose LuciDabra for a cutting-edge solution in the fight against advanced melanoma and NSCLC.